TTrialPathMatch Me to Trials
← Back to trials
RecruitingEndometriosisDiagnosis

Proof of Concept Study to Eval MetriDx Lab-developed Test to Identify Endometriosis-specific Bio Markers

Eligible age

18–50 yrs

Accepts

Women

Locations

2 states

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study is testing a way to diagnose endometriosis using a uterine tissue biopsy (similar to a pap smear) as opposed to undergoing laparoscopy surgery. The tissue is sent to lab for cellular analysis with a proprietary AI (artificial intelligence) technology.

Sponsor: Hera Biotech, Inc.

You may qualify if…

  • Able to understand and provide informed consent.
  • Natural born female of childbearing potential.
  • Age between 18 and 50, inclusive.
  • Not pregnant at Visit 0 (screening) or Visit 1 (day of procedure).
  • Free of systemic or pelvic disorder that, in the opinion of the investigator, may interfere with the tissue collection procedure, analysis of the tissue or increase the risk to subject.
  • Must not have received excision or ablation surgical procedure or treatment, such as gonadotropin-releasing hormone (GnRH), for endometriosis within the past 12 months.
  • For Cohort 1 and 2:
  • Suspected of having endometriosis, or previously diagnosed with endometriosis, and currently recommended for laparoscopic surgery by physician.

You may not qualify if…

  • Younger than 18 or 51 years or older.
  • Surgical history of hysterectomy.
  • Has received excision or ablation surgical procedure or treatment, such as gonadotropin-releasing hormone (GnRH), for endometriosis within the past 12 months.
  • Cohort 3: Prior diagnosis of endometriosis, or surgical note from prior laparoscopy that indicates endometriosis lesions were observed.
  • Has a BMI 40 or above.
  • Is currently taking a blood thinner medication.
  • Currently, pregnant, breast feeding, or has given birth in the last 6 months.
  • Diagnosed with HIV, AIDS, hepatitis A, B, or C, or has active malignancy.

Where it's recruiting

Michigan

Saginaw

Texas

Corpus Christi · Houston

Source: ClinicalTrials.gov · NCT05698212 · last updated 2023-01-26